SCHEMBL14113154

SCHEMBL14113154

CS(=O)(=O)Nc1ccc(Cl)cc1C(=O)Nc1cccc(C(F)(F)F)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX1 P51575 3/20 0.66
▸ SLC2A1 P11166 1/20 0.66
▸ P2RX4 Q99571 1/20 0.66
▸ P2RX7 Q99572 1/20 0.66
▸ TMPRSS4 Q9NRS4 1/20 0.66
▸ MEN1 O00255 3/20 0.62
▸ KMT2A Q03164 3/20 0.62
▸ CYP1A2 P05177 1/20 0.62
▸ POLB P06746 1/20 0.62
▸ CYP3A4 P08684 1/20 0.62
▸ CYP2C9 P11712 1/20 0.62
▸ CYP2C19 P33261 1/20 0.62
▸ RXFP1 Q9HBX9 8/20 0.57
▸ SLC20A2 Q08357 1/20 0.57
▸ SLC20A1 Q8WUM9 1/20 0.57
▸ PPARG P37231 1/20 0.57
▸ PPARD Q03181 1/20 0.57
▸ NR1H4 Q96RI1 1/20 0.57
▸ MPO P05164 1/20 0.57
▸ GRIK1 P39086 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5115424 0.87 SLC20A2 (0.66) P2RX1SLC2A1P2RX4P2RX7TMPRSS4
SCHEMBL6432352 0.84 NTRK1 (0.68) MEN1KMT2ACYP1A2POLBCYP3A4
SCHEMBL18341272 0.84 TMPRSS4 (0.54) P2RX1SLC2A1P2RX4P2RX7TMPRSS4
SCHEMBL330629 0.80 TMPRSS4 (1.00) P2RX1SLC2A1P2RX4P2RX7TMPRSS4
SCHEMBL29386800 0.80 TMPRSS4 (1.00) P2RX1SLC2A1P2RX4P2RX7TMPRSS4
SCHEMBL5117189 0.79 SLC10A6 (0.72) P2RX1SLC2A1P2RX4P2RX7TMPRSS4
SCHEMBL7126685 0.79 SLC20A2 (0.83) P2RX1SLC2A1P2RX4P2RX7TMPRSS4
SCHEMBL5119995 0.78 RXFP1 (0.70) MEN1KMT2ARXFP1SLC20A2SLC20A1
SCHEMBL5496729 0.78 MEN1 (0.72) P2RX1SLC2A1P2RX4P2RX7TMPRSS4
SCHEMBL17350344 0.78 SMO (0.48) P2RX1P2RX4P2RX7TMPRSS4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080167347-A1 Antidiabetic, antiproliferative, anticancer agents; benzanilide derivatives SHIONGI & CO., LTD. (JP) 2008-07-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167347-A1 Antidiabetic, antiproliferative, anticancer agents; benzanilide derivatives CCNY, HDGF, GLI1 P2RX1 4778/4885SLC2A1 174/4885P2RX4 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback